Answers are grounded in this paper and cite their sources.
Background: Early lung cancer detection remains challenging. Low-dose CT screening reduces mortality but is limited by false positives and low uptake. Circulating miRNAs are stable blood biomarkers, but reproducibility is poor as most derive from non-tumor tissues. We hypothesized that miRNAs secreted by lung cancer cells would provide more grounded biomarkers. Methods: Small RNA sequencing was performed on paired intracellular and extracellular RNA from conditioned media of six NSCLC cell lines and non-malignant controls. Differentially expressed miRNAs enriched in cancer-derived fractions were identified. Candidates were validated in serum from NSCLC patients and controls by RT-qPCR and examined in TCGA cohorts. Pathway and survival analyses assessed relevance. Results: Extracellular miRNA profiles were conserved across NSCLC lines and distinct from intracellular profiles. A core set of 25 miRNAs was enriched in cancer-derived media. Five miRNAs (miR-10b, miR-25, miR-92a, miR-182, miR-375) were elevated in NSCLC serum and robustly expressed in TCGA tumors. Pathway analysis showed enrichment of PI3K–Akt and hypoxia signaling. Elevated miR-10b was associated with poorer survival. Conclusions: Lung cancer cells secrete a conserved miRNA set detectable in serum and tumors, linked to oncogenic pathways and survival. Cell-based profiling offers a strategy for developing plasma miRNA assays for lung cancer detection.
No takes yet. Share an insight, caveat, or question.
Dutta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: